Duality Biotherapeutics, Inc. (DualityBio-B) filed its monthly return for the period ended 30 April 2026, highlighting incremental equity issuance driven by option exercises while maintaining regulatory float requirements.

• Authorised Capital The authorised share capital stayed unchanged at 200 million ordinary shares with a par value of USD 0.0001, equivalent to total authorised capital of USD 20,000.

• Issued Shares A total of 189,800 new ordinary shares were issued during April through the exercise of employee stock options, expanding the issued share base to 90,427,814 shares. The month-on-month increase represents 0.21 % of outstanding equity. No treasury shares were held or cancelled during the period.

• Public Float The company confirmed compliance with the Main Board’s minimum 25 % public float threshold as at 30 April 2026.

• Equity Incentive Activity Under the Pre-IPO Equity Incentive Plan: – 189,800 options were exercised, generating HKD 1.34 million in proceeds. – 13,352 options were cancelled. – Outstanding options totaled 18,630,628, with capacity to issue a further 13,913,502 shares under the plan.

• No Other Instruments There were no movements in warrants, convertible securities, or other share-issuing arrangements during the month.

Overall, April’s activity resulted in a modest expansion of DualityBio-B’s share capital, funded solely through employee option exercises, while all regulatory and listing obligations were affirmed.